US Stock MarketDetailed Quotes
ATRA Atara Biotherapeutics
- 13.652
- -0.608-4.26%
Trading Nov 14 13:11 ET
78.63MMarket Cap-539P/E (TTM)
14.830High13.215Low75.45KVolume14.480Open14.260Pre Close1.04MTurnover1.58%Turnover RatioLossP/E (Static)5.76MShares39.50052wk High-0.87P/B65.29MFloat Cap6.50052wk Low--Dividend TTM4.78MShs Float1638.998Historical High--Div YieldTTM11.33%Amplitude4.965Historical Low13.793Avg Price1Lot Size
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
% Chg
No Data
Atara Biotherapeutics Stock Forum
Should see increased acitivity soon as all these large investors have interest in this comp...
good buy
Atara Biotherapeutics Announces $36 Million Registered Direct Offering
Atara Biotherapeutics (Nasdaq: ATRA) has announced a $36 million registered direct offering of common stock and pre-funded warrants. The offering, priced at $8.25 per share, represents a 15% premium to Atara's 7-day volume-weighted average price. Participants include existing top institutional investors and a new strategic investor from a large public biotechnology company. The proceeds wi...
Atara Biotherapeutics Announces Second Quarter 2024 Financial Results, Operational Progress and Leadership Update
Atara Biotherapeutics (Nasdaq: ATRA) reported Q2 2024 financial results and operational progress. Key highlights include:
1. Tab-cel® U.S. BLA accepted under Priority Review with PDUFA date of January 15, 2025.
2. ATA3219 studies in Lupus Nephritis and Severe Systemic Lupus Erythematosus to start Q4 2024; initial data expected mid-2025.
3. ATA3...
No comment yet